The Joint Council for Cosmetic Practitioners has had an interesting year.

As we know it was established to be the “self-regulator of the non-surgical aesthetic industry in England and the point of access for the public seeking information about this area of practice and where appropriate for raising concerns about practitioners.”

It has recently published its annual report for the period 2018 to 2019.

The report highlights some interesting points for those keen on understanding where our industry may be going and can be read in full here:


So how is it doing?

Author and chairman Professor David Sines has published an in-depth report which covers a wide range of activities that have been undertaken and relationships built.

But where are the issues, if any?

On the key target of the numbers of practitioners registered he says: “This year has provided a slow but steady flow of new practitioner registrants to the Practitioner Register. The number who have joined the register is below our predicted target growth trajectory. The reasons for this are:

  • Reduced confidence in the sector about the merits of joining PSA approved voluntary registers which has resulted in a delay of members from the corporate clinic chains joining the register. The JCCP remains in active dialogue with the key Clinic Chain CEOs.
  • Reluctance of health care professionals seeking to join a register alongside non-health care professionals (this matter has now been mitigated following the JCCP’s decision not to admit non-health care practitioners in respect of the more ‘risk-related’ treatments).
  • Slower than expected penetration and awareness raising in the sector.”

Despite these challenges the JCCP remains resilient and confident that it will attract an adequate number of registrants over the next twelve months to sustain its financial base and to demonstrate its commitment to public protection.

Prof Sines also says: “Staffing has continued to be a challenge for the JCCP due to the need to identify a recurrent and sustainable revenue stream to enable the recruitment of a CEO and supporting infrastructure”.

So, despite the JCCP remaining “solvent” it appears to be challenged with just the following donations received:

Galderma (UK) Ltd: £25,000, Merck (UK) Ltd: £5,000, Allergan (UK) Ltd: No amount recorded, Church Pharmacy Ltd: £7,500.00, Wigmore Medical Ltd: £7,500.00

Anyone who wants to understand what the JCCP is doing should read the report.